Moderna Goes Vertical

Moderna surged 177% on a Phase 3 cancer-vaccine win as Treasury calmed long yields and stocks bounced.

Author

Elie Zakhour
August 20, 2026

Market Snapshot

Get a Top Job Offer, Guaranteed (or tuition is free) | Apply Here

📉 Banana Bits

Market News

Treasury Bought the Dip

Wall Street finally broke its three-session losing streak, although “broke” may be doing unpaid promotional work. The S&P 500 finished at 7,707.98, up 0.21%; the Dow gained 0.22% to 53,463.05; and the Nasdaq added 0.16% to 26,331.09. Small caps did slightly better, with the Russell 2000 up 0.50%. It was a bounce, not a personality transplant, and the major indexes never strayed far from flat.

The main macro catalyst came from an unusual address: Treasury. Starting September 9, the department will at least double the maximum size of each liquidity-support buyback in the 10-to-20-year and 20-to-30-year sectors, from $2B to at least $4B. That helped calm a long end that had been under serious pressure, with the 30-year yield hitting its highest level since 2007 a day earlier. By 4 p.m., the 10-year yield was 4.655%, down 5.1 basis points, while the 30-year fell 8.9 basis points to 5.196%.

Here’s an important distinction though: this is market plumbing, not monetary morphine. Treasury can make older, less-liquid bonds easier to trade; it cannot delete the country’s debt or turn a buyback into QE. That matters because the Fed’s July minutes were resolutely un-cuddly. Three officials voted to raise rates by 25 basis points, and “many” thought additional tightening would likely be needed if inflation did not cool. Falling long yields and hawkish minutes can coexist: Treasury relieved pressure at the long end, while the Fed minutes kept policy-rate risk alive.

Healthcare supplied the day’s actual fireworks. Moderna surged 176.97% and Merck gained 12.60% after their personalized mRNA cancer therapy plus Keytruda met the primary and a key secondary endpoint in a 1,137-patient Phase 3 melanoma trial. It marks the first positive late-stage trial result for an mRNA cancer vaccine. That is genuine scientific de-risking. It is also not the same as a finished commercial model: detailed effect sizes and overall-survival data remain under wraps.

Everywhere else, the tape was aggressively selective. Estée Lauder jumped 16.30% as China demand, fragrance strength and better margins made its turnaround look real. Target and Lowe’s also rose after earnings. TJX fell 4.21% after a soft near-term outlook, while Keysight dropped 6.32% as investors focused on supply constraints despite strong earnings. In chips, Marvell rallied 9.9% on its Google custom-silicon pact as Broadcom slid 4.6%. The market was not buying “consumer” or “AI”; it was grading individual homework.

Cross-assets joined the relief trade. The dollar index dropped 0.84% to 98.80 and gold futures settled at $4,545.30, while Bitcoin surged about 6% Wednesday before extending the rally above $70,000 Thursday morning, briefly touching roughly $71,500. Oil moved the other way for a less cheerful reason: Middle East tensions and restricted Strait of Hormuz traffic pushed WTI up 1.1% to $85.83 and Brent up 0.7% to $91.62. So yes, markets got some relief. The inflation, fiscal and geopolitical tabs stayed open.

Peel Take: Wednesday was a plumbing rally, not a clean bill of health. Treasury can improve liquidity; it cannot erase a $40T debt load or make inflation cooperate. If the 30-year settles down and market breadth keeps widening, this bounce has legs. If yields snap back after the technical sugar rush, the green close was a rest stop.

What's Ripe

Moderna (MRNA) 176.97%

  • INTerpath-001 met its primary recurrence-free survival endpoint and key secondary distant-metastasis-free survival endpoint in 1,137 high-risk melanoma patients.

  • The read-through reaches well past melanoma: Merck and Moderna have nine Phase 2/3 INTerpath studies across melanoma, lung, bladder and kidney cancers; Barclays sees about $3B of melanoma sales in 2035.

  • Moderna’s Q2 revenue was only $145M against a $782M net loss. This trial may be the post-Covid growth engine investors wanted…but effect sizes, overall survival, manufacturing economics and regulatory timing still need answers.

  • Peel Take: The market didn’t just celebrate one melanoma result; it put a much higher value on Moderna’s broader oncology pipeline. Fair enough. But after a 177% face-melter, expectations are suddenly much higher for approval, manufacturing and success beyond melanoma. The science earned the celebration, but the commercial story still has homework. 

Estée Lauder (EL) 16.30% 

  • Fiscal Q4 sales rose 6% to $3.627B, organic growth was 5%, and adjusted EPS jumped to $0.39 from $0.09; above the roughly $0.32 consensus.

  • Fiscal 2027 guidance called for 3%–5% organic sales growth and adjusted EPS of $3.10–$3.35; the midpoint topped the $3.18 LSEG estimate.

  • Mainland China organic sales grew 7%, fragrance stayed strong, and full-year adjusted operating margin expanded 320 basis points to 11.2%. One beauty mark: tariff refunds added $0.07 to Q4 adjusted EPS.

  • Peel Take: “Beauty Reimagined” finally has receipts instead of a mood board. China is healing, fragrance is sturdy and cost cuts are reaching the income statement. The tariff refund deserves an asterisk, but 320 basis points of margin expansion is not something management can airbrush into existence.

What's Rotten

TJX Companies (TJX) 4.21%

  • TJX fell 4.21% even after Q2 sales rose 5.4% to $15.18B and adjusted EPS increased to $1.22. The problem was underneath the headline beat: comparable sales at Marmaxx, which includes T.J. Maxx and Marshalls, grew just 1%, with management calling some of the weakness self-inflicted.

  • TJX raised its full-year profit forecast, but Q3 adjusted EPS guidance of $1.30–$1.32 landed slightly below Wall Street expectations, giving investors more reason to focus on the Marmaxx slowdown than the quarterly beat.

  • Peel Take: TJX didn’t miss the quarter; it missed the vibe. The headline beat looked backward-facing once investors saw a 1% Marmaxx comp and a light near-term profit guide. Off-price demand is still holding up, but Wall Street wanted cleaner execution from the core banners.

Keysight (KEYS) 6.32%

  • This was not an earnings miss. Fiscal Q3 adjusted EPS was $3.07 versus $2.48 expected; revenue reached $1.85B versus $1.75B.

  • Orders jumped 56% to $2.091B, and Q4 guidance of $1.93B–$1.95B in revenue plus $3.34–$3.40 in adjusted EPS came in ahead of consensus.

  • Shares reversed an opening gain as supply constraints threatened to delay the conversion of booming AI and data-center orders into shipments. Great demand met an even greater valuation bar.

  • Peel Take: This was a bad price for a very good quarter. Demand is kicking the door down, but supply cannot hand out wristbands fast enough. The long-term AI-infrastructure read-through remains constructive; near term, the market wants revenue in the loading dock, not an impressive waiting list.

🧠 Technical Trip

Interview Q&A from Evercore

👉 Want 1-on-1 recruiting help from Evercore bankers & 5,000+ top mentors? Apply to WSO Academy

🦈 Deal Dispatch

M&A, IPOs, And Other Notable Transactions

Student Success Corner

Banana Brain Teaser

Previous

A company’s EBITDA increases by 20%, but its EV/EBITDA multiple falls from 10x to 8x. Assuming everything else stays the same, by what percentage does the company’s enterprise value change?

Answer: - 4%

Today

A company has $500 million of annual revenue and $75 million of accounts receivable. Approximately what is its DSO?

❝

The investor’s chief problem, and even his worst enemy, is likely to be himself.

Benjamin Graham

How Would You Rate Today's Peel?


Happy Investing,
Chris, Elie, Mitchell, Fernanda, Nick, & Patrick